Primary study · included by 1 review

Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.

Tang 2018 · Tang Huilin, Shi Weilong, Fu Shuangshuang, et al. · Cancer medicine · 2018

Included by

Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.

Non-Cochrane · aetiology · 2026 · cited as Tang 2018 · Table 1 (Included MA); References

Outcome this study informs	Pooled effect	Evidence	Certainty
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.17	NR	GRADE not reported
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.13 [1.03, 1.25]	20 studies · 4846088 participants	Low
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.84 [0.99, 3.42]	2 studies · 9114 participants	Moderate
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.12	NR	GRADE not reported
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.62	NR	GRADE not reported
Risk of bladder cancer With angiotensin-converting enzyme inhibitors vs Without angiotensin-converting enzyme inhibitors	RR 1.04 [1.00, 1.08]	4 studies · 2560819 participants	Very low
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.49	NR	GRADE not reported
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.27	NR	GRADE not reported
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.28	NR	GRADE not reported
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.25	NR	GRADE not reported
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.20	NR	GRADE not reported
Risk of bladder cancer With pioglitazone vs Without pioglitazone	OR 1.66	NR	GRADE not reported

1 including review in total.